Repurposed Old Drug for New Cancer Treatment

Phenformin, discontinued in the 1970s as a diabetes treatment, is now being investigated as an adjunct to cancer immunotherapies
Phenformin, discontinued in the 1970s as a diabetes treatment, is now being investigated as an adjunct to cancer immunotherapies

A new review article published in the journal Trends in Cancer is presenting a promising case for phenformin, an old diabetes drug related to metformin, being repurposed as an adjunct to new immunotherapy cancer treatments. A phase 1 clinical trial is already underway to test the safety of the combination treatment for skin cancer.

read more

eNose Predicts Immunotherapy Treatment Effectiveness

It's claimed the device achieves 85 percent accuracy in predicting which lung cancer patients will, or will not, respond to new immunotherapy treatments
It’s claimed the device achieves 85 percent accuracy in predicting which lung cancer patients will, or will not, respond to new immunotherapy treatments
Amsterdam University Medical Centers

An impressive new study is suggesting a simple breath analysis can accurately predict whether lung cancer patients will positively respond to novel immunotherapy treatments. Unlike current methods, which involve studying tissue samples, the new “eNose” device can offer diagnostic advice in less than 60 seconds. read more